Literature DB >> 1748125

In vitro activity of cefcanel versus other oral cephalosporins.

N X Chin1, J W Gu, H C Neu.   

Abstract

Cefcanel is a new orally absorbed cephalosporin. Its activity was compared with that of cefuroxime, cefaclor, cephalexin, and cefixime against gram-positive and negative aerobic and anaerobic bacteria. Cefcanel had excellent activity against methicillin-susceptible Staphylococcus aureus and Staphylococcus epidermidis, MIC90 1 micrograms/ml, superior to the other oral cephalosporins. However, methicillin-resistant staphylococci were resistant, MIC greater than or equal to 16 micrograms/ml. Streptococcus pyogenes and Streptococcus pneumoniae were inhibited by 0.015-1 micrograms/ml, concentrations comparable to other cephalosporins. Clostridium spp. were inhibited by 0.25 micrograms/ml, 8- to 128-fold lower concentrations than were found for other agents, but the MICs were greater than 64 micrograms/ml for Bacteroides spp. The MIC90 for Moraxella catarrhalis was 1 micrograms/ml, similar to cefuroxime but 16-fold greater than the MICs of cefixime. Escherichia coli and Klebsiella pneumonia which were high beta-lactamase producers were resistant, MICs greater than 64 micrograms/ml, and 50% of Enterobacter cloacae and Citrobacter freundii were resistant. Cefcanel was hydrolyzed by TEM-1, TEM-3 and Moraxella Bro-1 beta-lactamases. Escherichia coli containing TEM-1, 2, 3, 5, 7, and 9 had cefcanel MICs of greater than or equal to 16 micrograms/ml. Although cefcanel inhibited gram-positive species as well as or at lower concentrations than other cephalosporins, it lacked activity against gram-negative species that produced common plasmid beta-lactamase although it inhibited Haemophilus influenzae carrying TEM-1.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748125     DOI: 10.1007/bf01975825

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  3 in total

1.  In vitro activities of 15 oral beta-lactams against Klebsiella pneumoniae harboring new extended-spectrum beta-lactamases.

Authors:  M D Kitzis; N Liassine; B Ferré; L Gutmann; J F Acar; F Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

2.  Comparative antibacterial activity of the new cephalosporin cefcanel against anaerobic bacteria.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

Review 3.  beta-Lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug
  3 in total
  1 in total

1.  Evaluation of Virtual Screening Strategies for the Identification of γ-Secretase Inhibitors and Modulators.

Authors:  Alicia Ioppolo; Melissa Eccles; David Groth; Giuseppe Verdile; Mark Agostino
Journal:  Molecules       Date:  2021-12-28       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.